KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $2.5 billion.

  • Regeneron Pharmaceuticals' Cash & Equivalents rose 24.58% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 24.58%. This contributed to the annual value of $2.5 billion for FY2024, which is 8.86% down from last year.
  • Regeneron Pharmaceuticals' Cash & Equivalents amounted to $2.5 billion in Q3 2025, which was up 25.58% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Cash & Equivalents ranged from a high of $3.9 billion in Q1 2023 and a low of $1.4 billion during Q1 2021.
  • Its 3-year average for Cash & Equivalents is $2.5 billion, with a median of $2.5 billion in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 132.68% in 2022, then crashed by 42.94% in 2023.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Cash & Equivalents stood at $2.9 billion in 2021, then climbed by 7.63% to $3.1 billion in 2022, then dropped by 12.10% to $2.7 billion in 2023, then decreased by 8.86% to $2.5 billion in 2024, then climbed by 24.58% to $2.5 billion in 2025.
  • Its Cash & Equivalents was $2.5 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $3.1 billion in Q1 2025.